中国临床药理学杂志2017，Vol.33Issue(18)：1748-1750,1760,4.DOI:10.13699/j.cnki.1001-6821.2017.18.004
盐酸吡格列酮胶囊联合缬沙坦胶囊治疗代谢综合征的临床研究
Clinical trial of pioglitazone hydrochloride capsules combined with valsartan capsules in the treatment of metabolism syndrome
摘要
Abstract
Objective To observe the clinical efficacy and safety of pioglitazone hydrochloride capsules combined with valsartan capsules in the treatment of patients with metabolic syndrome.Methods A total of 48 patients with metabolic syndrome were randomly divided into control group (n =24 cases) and treatment group (n =24 cases).Control group was given metformin 1.0 g,qd,oral + valsartan 80 mg,qd,oral.Treatment group was treated with pioglitazone hydrochloride 15 mg,qd,oral + valsartan 80 mg,qd,oral.Two groups were treated for 3 months.The clinical efficacy,systolic blood pressure (SBP),diastolic blood pressure (DBP),serum total triglyceride (TG),low density lipoprotein cholesterol (LDL-C),high density lipoprotein cholesterol (HDL-C),fasting blood glucose (FPG),fasting insulin (FINS),insulin resistance index (HOMA-IR) and adverse drug reactions in two groups were compared between two groups.Results After treatment,the total efficacy rates in treatment and control groups were 91.67％ (22/24 cases) and 79.17％ (19/24 cases) with significant difference (P ＜0.05).After treatment,the main indexes in treatment and control groups were compared:the SBP were (140.74 ± 7.37),(146.34±7.46) mmHg;DBP were (89.58 ±4.36),(96.37 ±4.86) mmHg;TG were (1.65 ±0.23),(2.05 ±0.29)mmol · L-1;LDL-C were (2.43 ± 0.31),(2.97 _± 0.35) mmol · L-1;HDL-C were (1.74±0.22),(1.31 ±0.11)mmol · L-1;FPG were (5.27 ±0.75),(6.48 ±0.86)mmol · L-1;FINS were (6.73 ±0.89),(8.05 ± 1.12)pmol · L-1;HOMA-IR were (3.63 ±0.37),(4.15 ±0.32),the differences were statistically significant (all P ＜ 0.05).The adverse drug reactions in treatment group were mild facial edema and headache,which in control group were gastrointestinal reactions and dizziness.The incidences of adverse drug reactions in treatment and control groups were 8.33％ and 12.50％ without significant difference (P ＞ 0.05).Conclusion Pioglitazone hydrochloride capsules combined with valsartan capsules have a definitive clinical efficacy in the treatment of patients with metabolic syndrome,which can reduce the levels of blood lipids,blood glucose,blood pressure and insulin resistance,without increasing the incidence of adverse drug reaction.关键词
盐酸吡格列酮胶囊/缬沙坦胶囊/代谢综合征/安全性Key words
pioglitazone hydrochloride capsule/valsartan capsule/metabolism syndrome/safety分类
医药卫生引用本文复制引用
陈劲松,刘运阳,曾高峰,陈家显,郭丹..盐酸吡格列酮胶囊联合缬沙坦胶囊治疗代谢综合征的临床研究[J].中国临床药理学杂志,2017,33(18):1748-1750,1760,4.基金项目
国家医学教育发展中心医学研究课题基金资助项目(2010-24-03-009) （2010-24-03-009）
